Contineum Therapeutics (CTNM) Interest Expenses (2023 - 2026)

Contineum Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $24.0 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 306.87% year-over-year to $24.0 million in Q1 2026; TTM through Mar 2026 was $24.0 million, a 306.87% increase from a year earlier, with the FY2025 full-year figure at $48.0 million, up 34.92% from the prior year.
• Interest Expenses rose to $24.0 million in Q1 2026 per CTNM's latest filing, from $853000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $27.0 million in Q1 2024 and bottomed at $92000.0 in Q1 2023.
• The 4-year median for Interest Expenses is $2.9 million (2025), against an average of $9.0 million.
• Across the five-year window, Interest Expenses soared 29271.74% in 2024 and plunged 78.13% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $116000.0 in 2023, then increased by 8.62% to $126000.0 in 2024, then jumped by 576.98% to $853000.0 in 2025, then surged by 2718.99% to $24.0 million in 2026.
• Per Business Quant, the three latest CTNM Interest Expenses figures stand at $24.0 million (Q1 2026), $853000.0 (Q4 2025), and $19.9 million (Q3 2025).